Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS

Journal of Virology

Volumn 85, Issue 20, 2011, Pages 10617-10626

  Nishimura, Yoshiaki ^a   Shingai, Masashi ^a   Lee, Wendy R ^a   Sadjadpour, Reza ^a   Donau, Olivia K ^a   Willey, Ronald ^a   Brenchley, Jason M ^a   Iyengar, Ranjini ^a   Buckler White, Alicia ^a   Igarashi, Tatsuhiko ^b   Martin, Malcolm A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; ENVELOPE GENE; GENE SEQUENCE; GENETIC RECOMBINATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; CD4 LYMPHOCYTE COUNT; HIV-1; MACACA MULATTA; RECEPTORS, HIV; RECOMBINATION, GENETIC; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; PRIMATES; SIMIAE; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 80054967648     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05010-11     Document Type: Article

References (60)

1. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
2. Brown, C. R., et al. 2007. Unique pathology in simian immunodeficiency virus-infected rapid progressor macaques is consistent with a pathogenesis distinct from that of classical AIDS. J. Virol. 81:5594-5606.
3. Brumme, Z. L., et al. 2005. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J. Infect. Dis. 192:466-474.
4. Charpentier, C., T. Nora, O. Tenaillon, F. Clavel, and A. J. Hance. 2006. Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J. Virol. 80:2472-2482.
5. Cho, M. W., M. K. Lee, C. H. Chen, T. Matthews, and M. A. Martin. 2000. Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate. J. Virol. 74:9749-9754.
6. Connor, R. I., K. E. Sheridan, D. Ceradini, S. Choe, and N. R. Landau. 1997. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:621-628.
7. Dean, M., et al. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856-1862.
8. De Jong, J. J., A. De Ronde, W. Keulen, M. Tersmette, and J. Goudsmit. 1992. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J. Virol. 66:6777-6780.
9. Delobel, P., et al. 2005. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 38:382-392.
10. Endo, Y., et al. 2000. Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus. J. Virol. 74:6935-6945.
11. Fouchier, R. A., et al. 1992. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Virol. 66:3183-3187.
12. Ho, S. H., et al. 2007. Coreceptor switch in R5-tropic simian/human immunodeficiency virus-infected macaques. J. Virol. 81:8621-8633.
13. Ho, S. H., N. Trunova, A. Gettie, J. Blanchard, and C. Cheng-Mayer. 2008. Different mutational pathways to CXCR4 coreceptor switch of CCR5-using simian-human immunodeficiency virus. J. Virol. 82:5653-5656.
14. Huang, W., et al. 2008. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J. Virol. 82:5584-5593.
15. Huang, W., et al. 2009. Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals. AIDS Res. Hum. Retrovir. 25:795-802.
16. Hunt, P. W., et al. 2006. Prevalence of CXCR4 tropism among antiretroviraltreated HIV-1-infected patients with detectable viremia. J. Infect. Dis. 194: 926-930.
17. Igarashi, T., et al. 2003. Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages. J. Virol. 77:13042-13052.
18. Igarashi, T., et al. 2007. Although macrophage-tropic simian/human immunodeficiency viruses can exhibit a range of pathogenic phenotypes, a majority of isolates induce no clinical disease in immunocompetent macaques. J. Virol. 81:10669-10679.
19. Igarashi, T., et al. 1999. Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 MAb during a primary infection with a nonpathogenic virus. Proc. Natl. Acad. Sci. U. S. A. 96:14049-14054.
20. Igarashi, T., et al. 2003. Early control of highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys usually results in long-lasting asymptomatic clinical outcomes. J. Virol. 77:10829-10840.
21. Jensen, M. A., et al. 2003. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J. Virol. 77:13376-13388.
22. Karlsson, A., K. Parsmyr, E. Sandstrom, E. M. Fenyo, and J. Albert. 1994. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J. Clin. Microbiol. 32:364-370.
23. Keele, B. F., et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557.
24. Kemal, K. S., et al. 2003. HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc. Natl. Acad. Sci. U. S. A. 100:12972-12977.
25. Kirchhoff, F., et al. 1997. Simian immunodeficiency virus variants with differential T-cell and macrophage tropism use CCR5 and an unidentified cofactor expressed in CEMx174 cells for efficient entry. J. Virol. 71:6509-6516.
26. Liu, S. L., et al. 2002. Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS. J. Virol. 76: 10674-10684.
27. Margulies, B. J., D. A. Hauer, and J. E. Clements. 2001. Identification and comparison of eleven rhesus macaque chemokine receptors. AIDS Res. Hum. Retrovir. 17:981-986.
28. Mild, M., J. Esbjornsson, E. M. Fenyo, and P. Medstrand. 2007. Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch. J. Virol. 81:3369-3376.
29. Moyle, G. J., et al. 2005. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J. Infect. Dis. 191:866-872.
30. National Institutes of Health. 1985. Guide for the care and use of laboratory animals. Department of Health and Human Services publication no. NIH 85-23. National Institutes of Health, Bethesda, MD.
31. + T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc. Natl. Acad. Sci. U. S. A. 102:8000-8005.
32. + T-cell depletion during long-term progression to AIDS in simian immunodeficiency virus-infected macaques. J. Virol. 81:893-902.
33. + T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc. Natl. Acad. Sci. U. S. A. 101:12324-12329.
34. Nishimura, Y., et al. 2010. Generation of the pathogenic R5-tropic simian/ human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J. Virol. 84:4769-4781.
35. Nora, T., et al. 2007. Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment. J. Virol. 81:7620-7628.
36. O'Doherty, U., W. J. Swiggard, and M. H. Malim. 2000. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74:10074-10080.
37. + memory T cells in rapidly progressive simian immunodeficiency virus infection. J. Exp. Med. 200:1299-1314.
38. Pitcher, C. J., et al. 2002. Development and homeostasis of T cell memory in rhesus macaque. J. Immunol. 168:29-43.
39. Pollakis, G., et al. 2001. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J. Biol. Chem. 276:13433-13441.
40. Regoes, R. R., and S. Bonhoeffer. 2005. The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol. 13:269-277.
41. Reimann, K. A., et al. 1996. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70:6922-6928.
42. Ren, W., et al. 2010. Different tempo and anatomic location of dualtropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection. J. Virol. 84:340-351.
43. Resch, W., N. Hoffman, and R. Swanstrom. 2001. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 288: 51-62.
44. Richman, D. D., and S. A. Bozzette. 1994. The impact of the syncytiuminducing phenotype of human immunodeficiency virus on disease progression. J. Infect. Dis. 169:968-974.
45. Robertson, D. L., et al. 2000. HIV-1 nomenclature proposal. Science 288: 55-56.
46. Sadjadpour, R., et al. 2004. Induction of disease by a molecularly cloned highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimera is multigenic. J. Virol. 78:5513-5519.
47. Sagar, M., et al. 2009. Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J. Infect. Dis. 199:580-589.
48. Salazar-Gonzalez, J. F., et al. 2008. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 82:3952-3970.
49. Salazar-Gonzalez, J. F., et al. 2009. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206:1273-1289.
50. Samson, M., et al. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725.
51. Schuitemaker, H., et al. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66:1354-1360.
52. Shibata, R., et al. 1997. Infection and pathogenicity of chimeric simianhuman immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. J. Infect. Dis. 176:362-373.
53. Tersmette, M., and F. Miedema. 1990. Interactions between HIV and the host immune system in the pathogenesis of AIDS. AIDS 4(Suppl. 1):S57-S66.
54. van Rij, R. P., M. Worobey, J. A. Visser, and H. Schuitemaker. 2003. Evolution of R5 and X4 human immunodeficiency virus type 1 gag sequences in vivo: evidence for recombination. Virology 314:451-459.
55. van't Wout, A. B., et al. 1994. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J. Clin. Invest. 94:2060-2067.
56. Wilkin, T. J., et al. 2007. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin. Infect. Dis. 44:591-595.
57. Willey, R., M. C. Nason, Y. Nishimura, D. A. Follmann, and M. A. Martin. Neutralizing antibody titers conferring protection to macaques from a simian/ human immunodeficiency virus challenge using the TZM-bl assay. AIDS Res. Hum. Retrovir. 26:89-98.
58. Willey, R. L., et al. 1988. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol. 62:139-147.
59. Zhang, Y., et al. 2000. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 74:6893-6910.
60. Zhu, T., et al. 1993. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179-1181.